Search - tctmd.com

Displaying 1 - 20 of 90

Sort: Relevancy | Date

News Conference News ACC 2026

ORBITA-CTO: PCI Reduces Angina Symptoms in Sham-Controlled Trial

Michael O'Riordan

March 29, 2026

Presentation ACC 2026

Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina – (ORBITA-CTO) A randomized, placebo-controlled trial

Presenter: Sarosh Khan

March 29, 2026

News Conference News ACC 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Yael L. Maxwell

March 28, 2026

News Conference News ACC 2025

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

Caitlin E. Cox

April 02, 2025

News Conference News ACC 2025

WARRIOR: No Clear Answers on How to Best Treat INOCA

Yael L. Maxwell

March 29, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

News Conference News ACC 2024

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

Shelley Wood

April 07, 2024

News Opinion Editor's Corner ACC 2024

What’s Going to Be Hot at ACC 2024

Shelley Wood

April 01, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Conference News ACC 2023

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Yael L. Maxwell

March 09, 2023

News Conference News ACC 2023

AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup

L.A. McKeown

March 09, 2023

News Conference News ACC 2023

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Michael O'Riordan

March 06, 2023

News Conference News ACC 2023

On-site Machine Learning-Based FFRCT Feasible, Informative: TARGET

Caitlin E. Cox

March 04, 2023

News Conference News ACC 2023

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

Shelley Wood

March 04, 2023

News Conference News ACC 2022

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

Michael O'Riordan

April 13, 2022

News Conference News ACC 2022

FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses

Michael O'Riordan

April 06, 2022

News Conference News ACC 2022

Better Angina Relief With Complete PCI in STEMI and MVD

L.A. McKeown

April 02, 2022

Advertisement

ORBITA-CTO: PCI Reduces Angina Symptoms in Sham-Controlled Trial

Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina – (ORBITA-CTO) A randomized, placebo-controlled trial

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

WARRIOR: No Clear Answers on How to Best Treat INOCA

What’s Going to Be Hot at ACC 2025?

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

What’s Going to Be Hot at ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

On-site Machine Learning-Based FFRCT Feasible, Informative: TARGET

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses

Better Angina Relief With Complete PCI in STEMI and MVD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content